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Introduction
Autoimune Polyendocrinopathy-Candidiasis-Ectodermal Dys-
trophy Syndrome (APECED; OMIM 240300), or Autoimmune
Polyglandular Syndrome Type 1 (APS I) is a rare autosomal re-
cessive disorder with high penetrance, characterized by a vari-
able combination of destructive autoimmune phenomena (1, 2)
and caused by a number of different mutations in the autoim-
mune regulator (AIRE) gene, which maps to 21q22.3 (2).
Endocrine glands are mainly affected, in association with
chronic mucocutaneous candidiasis; therefore the progres-
sion of the disease will lead to variable degrees of failure of
parathyroid glands, adrenal cortex, gonads, pancreatic beta-
cells, thyroid, gastric parietal cells. Non-endocrine less fre-
quently associated conditions are represented by malabsorp-
tion, chronic active hepatitis, gastric parietal cell atrophy, and
pernicious anemia. The most characteristic ectodermal mani-
festations are dental enamel hypoplasia, pitted nail dystro-
phy, alopecia, keratopathy, and vitiligo. Two of the classical
triad of symptoms (hypoparathyroidism, mucocutaneous can-
didiasis, adrenocortical insufficiency) are required for the di-
agnosis (4). 
Segregation has been reported in some ethnic groups: the
Finnish population has the highest report of patients, (about
1:25.000 inhabitants) (5, 6), followed by Iranian Jews (1:9000)
(7) and Norvegian population (8). A small group of patients has
been reported in Italy to date, mainly in Sardinia (1:14000 in-
habitants) (9), the Salento area in the Puglia region in Southern
Italy (10) and the Veneto region in Northern Italy (1). Only one
affected family has been reported in Central Italy (11).
We report here three newly diagnosed patients affected by the
classic clinical features of the disease (from two families origi-
nating from Southern Italy), in which mutations in the AIRE
gene were found.
Clinical case 1
A 16-year-old girl (AC) from healthy consanguineous parents
originating from Calabria (Southern Italy, close to the Salento
area) was referred to our outpatient clinic by the Dermatologic
Unit, where she was hospitalized because of alopecia univer-
salis, for an evaluation of primary amenorrhea and hypocal-
caemia. 
She had a cerebrospinal meningitis at 18 months of age, and a
lymphadenitis from Mycobacterium tuberculosis at three years
of age; three pneumonia infection followed in the following four
years. At the age of seven, alopecia universalis, and nail dys-
trophy occurred, with an initial good response to oral corticos-
teroids. After two years a diagnosis of chronic autoimmune thy-
roiditis with subclinical hypothyroidism was made and for the
first time hypocalcaemia with hyperphosphatemia and inade-
quately low-normal parathyroid hormone (PTH) were reported
(serum calcium 7.6 mg/dL, n.v. 8.8-10.3, phosphorus 7.4
mg/dL, n.v. 3.5-5.6, PTH 11.2 pg/ml, n.v. 10-70), together with
a modest increase in serum transaminases and keratoconjunc-
tivitis; there was a worsening of the alopecia and nail dystro-
phy. Only l-thyroxine therapy was prescribed. 
Normal growth and school performance are reported until she
was 15 years old, with the only exception of abnormal suscepti-
bility to respiratory infections; at that time a marked asthenia
developed, and a seizure occurred, after which hypocalcaemic
tetany was diagnosed, in association with inadequate PTH lev-
els (11.4 pg/ml). She was hospitalized in an Internal Medicine
Unit, and therapy with oral calcium, and 25-hydroxy vitamin D
was started: clinical symptoms improved, and serum calcium
level increased, but did not returned to normal values. Basal
levels of circulating ACTH were normal (27 ng/mL, n.v. 10-49)
and cortisol, 17-OH progesterone, DEAS, were in the low-nor-
mal range, as well as urine cortisol levels; on the contrary, FSH
and LH were markedly increased (FSH 45 mU/L, LH 11.2
mU/L) with very low estradiol levels, suggesting a primary ovar-
ian failure. She did not have menarche; pubertal changes were
o ly limited (Tanner B2, G2) and her bone age showed a 2-
year delay with respect to chronologic age. A pelvic ultrasound
evealed ovaries with normal dimensions for age, and a transi-
tional uterus, and normal liver characteristics. However a mild
transaminase increase was still present, with no signs of
cholestasis and a positivity for anti-mithocondrial antibodies
was found, suggesting an autoimmune liver involvement; other
organ and non organ-specific antibodies were non detectable.
The following findings were obtained when the patients was re-
ferred to our Endocrine Unit after one year:
– marked positivity of anti-ovary, anti-adrenal, anti-thyroperoxi-
dase and anti-glutamic acid decarboxylase antibodies; nega-
tivity of all the non organ-specific antibodies except for a mild
positivity of the anti-mithocondrial antibodies;
– normoglycemia with impaired glucose tolerance, normal lev-
els of C-peptide and mild hyperinsulinemia;
– high-normal basal ACTH levels (74 ng/ml, n.v. <52) with low-
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— normal basal cortisol levels (162 nM, n.v. 160-690) and
serum sodium (135 mEq/L, serum potassium 4.1 mg/dL) and
no response to adrenocorticotropic hormone (ACTH test), in-
dicating a subclinical hypoadrenalism;
— normal levels of PRL, IGF-1 and osmolarity; high levels of
FSH and LH (117 and 53 U/L respectively);
— normal hepatic indexes (with transaminases in the high-nor-
mal limit) and normal liver appearance at ultrasound;
— in therapy with 25-OH vitamin D and calcium: high levels of
circulating 25-OH vitamin D (338 ng/mL, n.v. 11-70) with low
1,25-OH vitamin D (18.4 pg/mL, n.v. 20-67), with serum calci-
um of 8.2 mg/dL (n.v. 8.8-10.7) and calciuria of 110 mg/day
(n.v. 100-300);
— worsening of the keratoconjunctivitis; nail dystrophy;
— hypotension with normal basal and stimulated epinephrine
and norepinephrine values;
— no actual evidence for mucocutaneous candidiasis.
Analysis of mutations of the AIRE gene: homozygous mutation
C G Afi TGA at codon 203 in exon 5, causing an aminoacidic
substitution Argfi STOP in the protein. The same heterozygous
mutations. are present in both parents and the brother.
Cortone acetate and low-dose estrogens were added to l-thy-
roxine, and 25-hydroxy vitamin D was substituted by calcitriol,
0.03 mg/kg/day and low dose oral calcium. After one year there
were no signs of worsening of the disease; normocalcaemia
and normocalciuria were obtained, there was a progression of
pubertal status to Tanner stage III, and a growth spurt, with a
predicted final age in the same range of that of her parents.
There was a significant decrease in the number and severity of
recurrent infections; she recently reported the occurrence of di-
arrhoea with increasing frequency, and the possibility of malab-
sorption is under investigation.
Clinical cases 2 and 3
Case 2
A six years-old female (GR), was referred to our outpatient Unit
for the suspect of autoimmune polyendocrinopathy. The
healthy consanguineous parents are from the Puglia region, in
southern Italy, in an area close to the Salento area.
GR had a first seizure when she was one year old; hypocal-
caemia and hypophosphoremia were found. Calcium and vita-
min D were prescribed for a 2-week period, with no other mea-
surement of serum calcium and phosphorus levels. Infections
of the urinary tract presented for the first time, and were recur-
rent from that time till the present age.
The infant was well till one year later, when a second seizure
occurred. Hypoparathyroidism was diagnosed and therapy with
25-hydroxy vitamin D and calcium was started; thyroid hor-
mones, serum sodium and potassium were normal, as well as
serum glycemia and routine analysis. Alopecia presented, with
rapid progression to a generalized form.
When she was 4 years old GR was again hospitalized for
hypocalcaemia (7 mg/dL) with hyperphosphatemia (6.5 mg/dL -
she was on 25-hydroxy vitamin D and calcium therapy per os),
cervical polyadenopathy, respiratory and urinary tract infection,
onicodystrophy. Serum sodium level at the low-normal limit (133
mEq/L) high-normal potassium (5.0 mEq/L) with normal serum
cortisol were detected; upper respiratory tract candidosis was
diagnosed and nephrocalcinosis was found at ultrasound evalu-
ation. A reduction in NK T lymphocytes (CD16, CD56+), helper
lymphocytes (CD3+, CD4+) and B-lymphocytes, with increase
of CD3+ and CD8+ were found. Mutational analysis for DiGe-
orge Syndrome showed no alteration. Oral sodium supplements
were added to 25-hydroxy vitamin D and calcium. 
The evaluation performed at our Clinic showed:
– generalized alopecia, nail dystrophy and mucocutaneous
candidosis; decreased growth rate, more marked in the last
year, normal thyroid, no mental or intellectual deficits, ab-
sence of ocular involvement;
– marked positivity of anti-adrenal antibodies; negativity of the
other organ-specific and non organ-specific antibodies;
– hypoadrenalism with increase in basal ACTH levels (170
ng/dL, n.v. < 50), hyponatriemia (128 mE/L);
– hypocalcaemia (7.2 mg/dl), hyperphosphatemia (6.5 mg/dl)
and hypercalciuria (350 mg/day) with undetectable PTH lev-
els;
– normal thyroid function, PRL, IGF-1, LH, FSH, glycemia;
– nephrocalcinosis; no alteration in renal function; Escherichia
Coli urinary infection.
Therapy with hydrocortisone and calcitriol in substitution for 25-
hydroxy vitamin D were started, in addition to oral calcium, and
to appropriate therapy for candidosis and urinary tract infection.
After two years she has calcemia in the low-normal range and
normophosphatemia, with calciuria in the normal range, normal
serum sodium and potassium levels; she has normal growth
rate and school performances. There are no differences in cir-
culating autoantibodies except for a mild positivity of glutamic
acid decarboxilase antibodies. Oral candidosis is not de-
tectable; urinary tract infections are recurrent.
Case 3
The previous healthy seven years-old brother of case 2 (VR)
had a hypocalcemic tetanic crisis one week before the sister’s
visit at our Clinic, and therefore he was evaluated at the same
time:
– normal growth velocity, mental and school performances; ab-
sence of ocular problems, euthyroidism, normoglycemia;
– hypoparathyroidism;
– mild oral candidosis;
– slight positivity for antiadrenal antibodies; negativity of an-
tithyroid, anti glutamic acid decarboxylase, antiparietal cells,
and non organ specific antibodies;
– normal circulating ACTH and cortisol levels, and normal corti-
sol response to ACTH administration.
After two years of treatment with calcitriol and calcium there
are no variation in the pattern of circulating autoantibodies, nor
a worsening in adrenal basal and stimulated funtion. Oral can-
didosis is not evident.
Analysis of mutations of the AIRE gene: in both children is pre-
sent a homozygous mutation Thrfi Met at codon 16 in exon 1
and a heterozygous mutation Prolfi Leu at codon 252 in exon
6. The mother has the heterozygous mutation Thrfi Met at
codon 16 in exon 1; the father showed both heterozygous mu-
tations. They have normal parathyroid and adrenal function as
well as euthyroidism and normoglicemia and absence of ecto-
dermal dystrophies.
Discussion
APECED is the first multiple autoimmune disease caused by a
defect in a single gene, the autoimmune regulator AIRE; the
protein acts as a transcription activator and its genomic target
and functions have not been fully elucidated yet. The three
c es described here, from two unrelated families originating
from areas close to that of the previously described APECED
patients in Southern Italy (10), point out interesting aspects of
th  disease in relation to both diagnostic and therapeutic prob-
l ms.
The majority of described cases of APECED are familial, with
an autosomal recessive mode of inheritance; in the two fami-
lies studied there is a negative anamnesis for APECED-related
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diseases. The clinical spectrum in patients with APECED is
broad; within a single family, it has been reported a variation of
symptoms between affected sibling. The disease usually oc-
curs in childhood, and the prevalence of most disease compo-
nents increases with age; new tissue-specific symptoms may
appear at any age (4); in some cases the disease may become
clinically recognizable only in adulthood. The frequent presen-
tation with dermatological problems associated to the mild
signs that are generally associated to chronic hypocalcaemia
or hyponatremia or to recurrent respiratory or urinary tract in-
fections before an acute, life-threatening hypocalcemic or hy-
poadrenal crisis can determine a wrong initial approach to the
disease, leading to errors in diagnosis, or a delay in the recog-
nition of the disease, and to underestimation of the importance
of life-long follow-up. The delay in the diagnosis can also influ-
ence therapeutic errors, such as the choice of 25-hydroxy vita-
min D for the management of hypocalcaemia; in the absence
of PTH, it is difficult to obtain normocalcemia, with the risk of
prolonging the clinical problems related of hypocalcaemia (2).
The recognition of subclinical hypoadrenalism is also very diffi-
cult for the lack of specific signs for a long period. The suspect
of the disease must prompt the assay of plasma ACTH and
cortisol levels and an ACTH test, even in the presence of low-
normal serum electrolytes, allowing an early beginning of corti-
sone acetate therapy. The little correlation between the pres-
ence of antibodies and the clinical manifestations of APECED,
even among members of a same kindred contributes to the di-
agnostic and therapeutic difficulties; the detection of antibodies
in affected individuals may precede eventual endocrine defi-
ciencies; the significance of autoantibodies detection in appar-
ently healthy family members is unclear.
Another important clinical aspect of the disease is represented
in our patients by the observation that the earlier the first com-
ponent appears, the more likely is the development of multiple
manifestations; late manifestations of the disease are likely to
have fewer components (4, 12). This explains the necessity of
an aggressive diagnostic effort in pediatric patients, in order to
an early detection of adrenal failure, hypoparathyroidism or dia-
betes. 
The understanding of the relevance of major mutations of the
AIRE gene to the different pattern of clinical disorders associat-
ed to APECED and the analysis of a possible clustering of mu-
tations in definite subpopulations will represent an important
contribution to the management of the disease and may be-
come an important tool in its early detection. The stop codon
mutation in our clinical case 1 (C203T in exon 5) was previous-
ly detected only in two affected siblings of Northern Italy in
compound heterozigosity with R257X (a common cause of
APECED in Northern Italian and Finnish patients) (13); it was
of maternal origin. R257X and R203X are both situated before
the first zinc finger motif in the AIRE gene. In this family, the
two siblings had a similar disease progression except for the
lack of hypoparathyroidism in one of them (up to the time of the
report). AC, now seventeen years old, shows a serious multi-
systemic involvement from the disease: hypoparathyroidism,
adrenal, thyroid and ovarian failure, incoming diabetes mellitus,
worsening keratoconjunctivitis, generalized alopecia, nail dys-
trophy, and the suspect of developing hepatic and gastroin-
testinal involvement. There are no actual signs of candidosis.
The T16M homozygous missense mutation in exon 1 in cases
2 and 3 and their mother was previously described (14) in a
Russian patient in heterozigosity with the mutation R257X; he
was affected, at time of the report, by hypoparathyroidism, Ad-
dison disease, hypothyroidism and mucocutaneous candidosis.
Like other missense mutations it seems to accumulate to the
N-terminal HSR domain-coding region. 
The missense mutation P252L in exon 6 (cases 2 and 3) has
been described in one patient from the Salento region in Italy in
a compound heterozygous state with the W78R mutation (10).
Interestingly, the paternal grandparents of this patient come
from the Naples area, as well as those of the father of the
probands, also presenting the same mutation. This mutation
lies in the amino-terminal SAND domain, a DNA-binding do-
main, and it probably results in the alteration of the secondary
structure of the gene related to its proline-rich composition. GR
and AR are now 8 and 9 years old, so the pattern of the dis-
e se can be subjected to variations. However, GR presented
serious and early manifestations of the disease, similar to our
case 1, while VR still has only parathyroid involvement and
mild positivity of anti-adrenal antibodies with normal basal and
stimulated function.
In conclusion, the clinical expression is highly variable in pa-
tients with APECED and in addition some of the manifestation
c n appear up to the fifth decade; these characteristics lead to
life-long diagnostic and therapeutic problems. Improving knowl-
edge of genotype-phenotype correlations will lead to a better
understanding and a follow-up of the different patterns of the
disease (15). 
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